Myriad Genetics

MYGN · NASDAQ

$5.54+$1.33 (+31.59%)TodayMarket closed ·
Prev close $4.21

Key indicators

MYGN profitability and balance sheet ratios

EPS -$0.4557 in Q2 FY26, against -$3.57 a year earlier.

EPS by quarter
PeriodEPS
Q3 FY24-$0.2418
Q4 FY24-$0.4675
Q1 FY25-$0.0011
Q2 FY25-$3.57
Q3 FY25-$0.2943
Q4 FY25-$0.0845
Q1 FY26-$0.3639
Q2 FY26-$0.4557

Where the money went

Q2 FY26, from revenue to net income

Myriad Genetics brought in $190.7M of revenue in Q2 FY26, −10.5% on a year earlier. It made a net loss of $43.2M.

Revenue
$190.7M
Costs, expenses and taxes
$233.9M
Net income
−$43.2M
Net margin
-22.7%

Income statement

Revenue and profit by reporting period

Revenue
Net income
MYGN income statement, quarterly
Line itemQ4 FY25Q1 FY26Q2 FY26
Revenue$209.8M$200.4M$190.7M
Gross profit$146.8M$137.6M$127.0M
Operating income−$5.7M−$30.7M−$38.9M
Net income−$7.9M−$34.1M−$43.2M
Diluted EPS-$0.08-$0.36-$0.46

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
MYGN balance sheet, quarterly
Line itemDec 2025Mar 2026Jun 2026
Total assets$706.6M$673.7M$638.9M
Total liabilities$338.6M$336.3M$335.0M
Shareholder equity$368.0M$337.4M$303.9M
Cash and short-term investments$149.6M$124.4M$115.2M
Total debt$119.9M$120.3M$120.7M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
MYGN cash flow, quarterly
Line itemQ4 FY25Q1 FY26Q2 FY26
Operating cash flow$10.6M−$15.7M−$8.3M
Investing cash flow−$6.0M−$6.5M−$3.2M
Financing cash flow−$8.2M−$3.0M$2.2M
Capital expenditure−$4.7M−$5.4M−$2.1M
Free cash flow$5.9M−$21.1M−$10.4M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.